The persistence of national drug shortages in the United States has evolved from a temporary operational challenge for hospital pharmacies into a chronic public health and national security crisis. Across the country, healthcare systems must continuously ration essential medications, postpone surgeries, swap standard chemotherapy protocols, and manage complex clinical workarounds.
For hospital pharmacy directors, pharmaceutical supply chain executives, healthcare policy analysts, and generic drug developers, understanding the scope of this crisis requires looking past headline political statements. Achieving this level of insight requires a systematic, registry-level analysis of the FDA Drug Shortages database: which molecules are unavailable, which dosage forms represent the greatest points of failure, which manufacturers concentrate the highest supply-chain risk, and how long these shortages actually persist.
To build a comprehensive and reproducible picture of the current supply landscape, we conducted a detailed analysis of the U.S. FDA Drug Shortages registry. Reconciling the FDA registry against the latest annual reports from the U.S. Pharmacopeia (USP), the American Society of Health-System Pharmacists (ASHP), and the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) exposes the economic forces and policy gaps that sustain the shortage crisis. For our qualitative analysis of what is driving these dynamics, see what's in short supply: FDA drug shortage analysis.
Supply Chain Executive Summary
- How many drug shortages are active? The FDA Drug Shortages registry contains 1,629 presentation-level entries. Of these, 1,175 are active ("Current") shortages, 429 represent presentations "To Be Discontinued", and 25 are marked as "Resolved". These entries map to 73 distinct generic molecules currently in active national shortage.
- How long do drug shortages last? The duration of active shortages is long. The median active shortage has persisted for 1,684 days (4.6 years). The longest active shortage in the registry has lasted 14.6 years (5,320 days). Crucially, 1,140 of the 1,175 active shortages (97.0%) have persisted for more than two years.
- Which dosage forms are most affected? Sterile injectables represent the primary point of failure. The registry contains 1,002 injectable presentation entries, of which 831 are actively in short supply. This aligns with the U.S. Pharmacopeia's 2026 finding that injectables account for 71% of all active shortages.
- Which therapeutic categories face the highest exposure? Active shortages are concentrated in Anesthesia (347 active entries), Pediatric formulations (272 active entries), and Psychiatry medications (260 active entries).
- Which manufacturers are most concentrated in the registry? Supply risk is highly concentrated among a small cohort of generic injection manufacturers: Hospira (a Pfizer Company) leads with 166 active entries, followed closely by Fresenius Kabi USA with 160 active entries, and Hikma Pharmaceuticals USA with 97 active entries.
- How does this compare to other shortage metrics? The FDA presentation-level count of 1,175 entries reflects national NDC-level packaging shortages, which differs from ASHP's count of ~200 active molecules in shortage or USP's focus on broader drug class discontinuations.
How many active drug shortages are on the FDA list, and how is that counted?
Our systematic filter of the FDA Drug Shortages registry identified exactly 1,629 total presentation-level entries in the database. When evaluating drug shortages, the unit of analysis is critical. The FDA database reports shortages at the presentation level—meaning specific drug strengths, package sizes, and National Drug Codes (NDCs) rather than broad generic molecules.
The table below breaks down the 1,629 registry records by their current clinical status:
| Shortage Status | Entry Count | Share of Registry (%) | Supply Chain Implication |
|---|---|---|---|
| Current (Active) | 1,175 | 72.1% | Products are actively unavailable or in severely limited supply nationally. |
| To Be Discontinued | 429 | 26.3% | Manufacturers have notified the FDA of intent to permanently cease production. |
| Resolved | 25 | 1.6% | Supply has returned to baseline levels, but records are kept for historical tracking. |
| Total Registry Entries | 1,629 | 100.0% | Comprehensive presentation-level shortage database. |
Within the 1,175 active shortages, we isolated 73 distinct generic molecules (such as bupivacaine, cisplatin, albuterol, and dextrose). The difference between 1,175 active presentation shortages and 73 active molecules is driven by packaging variation. For example, a single generic molecule like bupivacaine hydrochloride can have a dozen or more separate entries in the registry, representing different concentrations (e.g., 0.25%, 0.5%, 0.75%), different volumes (e.g., 10 mL, 20 mL, 50 mL vials), and different packaging styles (e.g., preservative-free, dental cartridges, or standard multi-dose vials).
This presentation-level granularity is essential for clinical operations. A hospital pharmacy cannot simply substitute a 50 mL vial of 0.5% bupivacaine with a 10 mL vial of 0.25% bupivacaine without altering clinical dosing protocols, syringe pump programming, and compounding workflows. Therefore, tracking presentation-level shortages provides a much more accurate reflection of health-system supply friction than molecule-level counts alone.
How long do drug shortages last, and how has duration changed?
The most striking and clinically concerning characteristic of the current shortage crisis is the duration of active shortages. The FDA registry data reveals that shortages are no longer short-term disruptions that resolve in a matter of weeks or months; instead, they have become structural market fixtures.
Our analysis of the active shortages (duration calculated from each shortage's initial FDA posting date to the snapshot date of July 26, 2026) yielded the following stats:
- Median Active Shortage Duration: 1,684 days (4.6 years).
- Maximum Shortage Duration: 5,320 days (14.6 years), representing a legacy injection presentation that has remained unresolved since 2011.
- 90th Percentile (P90) Duration: 3,289 days (9.0 years).
- The Long-Term Shortage Share: Exactly 1,140 of the 1,175 active shortages (97.0%) have lasted longer than two years (730 days).
The table below illustrates the distribution of active shortage durations:
| Shortage Duration Range | Entry Count | Share of Active Shortages (%) | Representative Shortage Examples |
|---|---|---|---|
| Less than 1 Year | 12 | 1.0% | Newer supply disruptions, often raw material delays. |
| 1 to 2 Years | 23 | 2.0% | Mid-term shortages, typically driven by minor regulatory holds. |
| 2 to 5 Years | 575 | 48.9% | Long-term shortages; includes major sterile injectable classes. |
| 5 to 10 Years | 470 | 40.0% | Structural shortages; driven by single-supplier exits. |
| More than 10 Years | 95 | 8.1% | Legacy shortages; molecules with severe manufacturing economics. |
| Total Active Shortages | 1,175 | 100.0% | 97% of active shortages have lasted >2 years. |
This duration profile points to a market that is failing to self-correct. In a functional economic market, a shortage drives prices up, which encourages existing manufacturers to expand capacity or new entrants to capture market share, eventually resolving the shortage.
In the generic sterile injectable market, however, buyer consolidation (specifically, the dominance of three Group Purchasing Organizations, or GPOs, which control over 90% of hospital drug purchasing) has driven prices down to near-commodity levels. Manufacturers cannot justify investing millions of dollars to upgrade manufacturing facilities or build redundant capacity for drugs that yield pennies in profit margin.
Which dosage forms and therapeutic categories are most affected?
Analyzing the registry by dosage form and therapeutic category highlights where supply risk is concentrated. Sterile injectables represent the primary point of failure in the national drug supply chain.
Dosage Form Breakdown: Injectables Lead the Failure
The FDA registry tracks shortages across all dosage forms. However, the operational complexity of sterile manufacturing makes injectables uniquely vulnerable. The table below details the registry entries by primary dosage form:
| Dosage Form | Total Entries | Active Shortages | Active Share of Form (%) | Primary Clinical Examples |
|---|---|---|---|---|
| Injection | 1,002 | 831 | 82.9% | Local anesthetics (bupivacaine, lidocaine), emergency syringes, chemo (cisplatin). |
| Tablet | 350 | 178 | 50.9% | Cardiovascular, psychotropic, and endocrinology tablets. |
| Capsule | 140 | 105 | 75.0% | Oncology and neurology capsules (including ADHD stimulants). |
| Tablet, Chewable | 19 | 18 | 94.7% | Pediatric formulations and chewable antibiotics. |
| Solution / Oral Susp | 33 | 10 | 30.3% | Liquid pediatric medications, oral solutions. |
| Other (Ophthalmic, Suppository, Irrigant, etc) | 85 | 33 | 38.8% | Ophthalmic solutions, topical creams, suppositories, irrigants. |
| Total Registry | 1,629 | 1,175 | 72.1% | Comprehensive dosage-form analysis. |
Sterile injectables account for 1,002 total entries and 831 active shortages, representing over 70% of the active shortage volume. Generating sterile injectables requires specialized cleanrooms, aseptic filling equipment, sterile raw materials, and extensive quality control testing to prevent bacterial contamination or particulate introduction. A single quality issue (such as finding glass shards in a vial or mold on a filling line) can halt production for months, immediately triggering a national shortage.
Therapeutic Category Breakdown: Anesthesia and Pediatrics Exposed
Aggregating the 1,175 active shortages by therapeutic category reveals that the shortage crisis is concentrated in high-stakes clinical areas:
- Anesthesia (347 active entries): The largest active category in the registry. Includes local anesthetics (bupivacaine, lidocaine, ropivacaine) and critical surgical induction agents (propofol, midazolam, fentanyl). Shortages in this category directly delay surgeries and force clinics to use alternative agents that may increase recovery times.
- Pediatric (272 active entries): Includes specialized liquid formulations, electrolyte solutions for neonatal intensive care units (NICUs), and pediatric chemotherapy.
- Psychiatry (260 active entries): Heavily influenced by the ongoing shortage of ADHD stimulants (methylphenidate, amphetamine mixed salts), alongside generic antipsychotics and anti-anxiety medications.
- Gastroenterology (140 active entries): Includes intravenous lipid emulsions, saline, and electrolyte injection bags used for Total Parenteral Nutrition (TPN) in patients who cannot eat solid food.
- Analgesia/Addiction (128 active entries): Focuses on injectable opioids used for post-operative pain management, alongside methadone and buprenorphine.
- Oncology (81 active entries): Though smaller in presentation counts, oncology shortages carry high clinical risk. Active shortages include cisplatin, carboplatin, and methotrexate—first-line chemotherapies with no equivalent clinical substitutes.
For an in-depth clinical analysis of the anesthesia vertical, which represents the single largest shortage category in our registry cut, see our dedicated anesthesia injectable shortage analysis.
Which manufacturers are most concentrated in the shortage list?
The supply chain for generic sterile injectables is highly consolidated. A small group of manufacturers produces the majority of the nation's generic injections. Consequently, when a single facility owned by one of these major players experiences a manufacturing shutdown or quality recall, the entire national healthcare system feels the impact.
Our analysis of the active shortages by manufacturer reveals a high level of concentration:
- Hospira, Inc. (a Pfizer Company): 166 active entries. Hospira's sterile injectables plant in Rocky Mount, North Carolina, is one of the largest in the world.
- Fresenius Kabi USA, LLC: 160 active entries. A major global provider of generic sterile injections, infusion therapies, and clinical nutrition.
- Hikma Pharmaceuticals USA, Inc.: 97 active entries. A leading manufacturer of generic injectables and non-injectable generics in the US.
- Baxter Healthcare: 67 active entries. Baxter is a dominant supplier of large-volume intravenous solutions, saline bags, and sterile water.
- Teva Pharmaceuticals USA, Inc.: 44 active entries. Teva represents a major supplier of both solid oral doses and generic sterile injectables.
- Pfizer Inc.: 43 active entries (registered under "Pfizer Inc." separate from "Hospira, Inc.", bringing the total Pfizer corporate footprint to 209 active entries).
- Eugia US LLC (formerly Aurobindo): 42 active entries. A rapidly growing generic injectable manufacturer.
This manufacturer concentration highlights the vulnerability of the US drug supply chain. The top three companies—Pfizer/Hospira, Fresenius Kabi, and Hikma—account for a combined 423 active shortages, representing 36% of all active shortages in the country. For generic manufacturers weighing capacity entry, these persistent gaps define an opportunity ledger for sterile-injectable capacity.
How does the FDA-list count compare with USP, ASHP, and ASPE figures?
When pharmacy leaders and policymakers quote drug shortage statistics, they often cite conflicting numbers. This confusion arises because different organizations track drug shortages using different methodologies, definitions, and units of analysis. Reconciling these numbers is essential for accurate policy formulation.
1. The FDA Drug Shortages Database
- Unit of Analysis: Presentation-level (NDC-level packaging).
- Criteria: Focuses on medically necessary products where the supply cannot meet national demand.
- Current Volume: 1,175 active shortages.
- Method Limit: The FDA list tracks shortages at the packaging level. While it overstates the number of unique molecules in short supply, it provides the most operationally useful data for hospital procurement teams trying to buy specific vial sizes.
2. The U.S. Pharmacopeia (USP) annual report
- Unit of Analysis: Drug class and molecule level, with a focus on systemic market health.
- Key 2026 Findings (Published June 9, 2026): The USP report found that the median duration of active shortages rose to 5.0 years in 2025 (up from 4.3 years in 2024 and just 2.0 years in 2019). While the total number of active shortages fell by 23%, new drug discontinuations rose by 60% year-over-year.
- Reconciliation: The USP's 5.0-year median duration closely aligns with our registry-computed median of 4.6 years (1,684 days). The slight difference reflects the USP's exclusion of non-drug diagnostic tracers and minor topical presentations, which isolates the longest-standing drug molecules.
3. The American Society of Health-System Pharmacists (ASHP) / Utah Drug Information Service
- Unit of Analysis: Molecule level.
- Criteria: Tracks any supply disruption, regardless of whether it is deemed medically necessary or has an available alternative.
- Current Volume: Historically hovers around 200 to 250 active molecules in shortage.
- Reconciliation: ASHP's count is significantly higher at the molecule level because it registers a shortage as soon as any pharmacy reports difficulty procuring a drug, whereas the FDA only lists a shortage once it confirms a national supply-demand mismatch.
4. The HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE)
- Unit of Analysis: Longitudinal molecule analysis.
- Key Findings (HHS ASPE Data Brief): Isolated 258 distinct molecules that entered a national shortage between 2018 and 2023. The ASPE brief found that sterile injectables were 50% of all shortages, and 65% of injectable shortages remained unresolved after three years (compared to only 8% for oral solid formulations).
- Reconciliation: The ASPE analysis confirms the unique vulnerability of injectables, which is reflected in our registry data where injectables represent 71% of the active shortage volume (831 active entries).
To track how hospital pharmacy operations manage these discrepancies and navigate the daily changes on the FDA shortage list, see our operational guide: FDA drug shortage list reading workflow.
What policy and market forces are driving persistent shortages?
To understand why the median drug shortage in the United States persists for nearly five years, one must analyze the market economics and regulatory hurdles that shape generic manufacturing.
+-------------------------------------------------------------------+
| Generic Price Erosion |
| (Driven by GPO consolidation & aggressive cost-cutting contracts)|
+----------------------------------------+--------------------------+
|
v
+-------------------------------------------------------------------+
| Under-Investment in Facilities |
| (Low margins prevent capital upgrades to aging sterile plants) |
+----------------------------------------+--------------------------+
|
v
+-------------------------------------------------------------------+
| Manufacturing Quality Failures |
| (FDA inspections reveal contamination, particulate, or mold) |
+----------------------------------------+--------------------------+
|
v
+-------------------------------------------------------------------+
| Supply Disruption & Shortage |
| (Single-site shutdowns trigger systemic, multi-year shortages) |
+-------------------------------------------------------------------+
The Economic Race to the Bottom
Generic drugs represent approximately 90% of all prescriptions written in the United States, yet they account for only 10% of total drug spending. For generic sterile injectables, buying power is consolidated within three major Group Purchasing Organizations (GPOs)—Vizient, Premier, and HealthTrust—which negotiate purchasing contracts on behalf of hospital networks.
By prioritizing the lowest cost above all other metrics, these GPO contracts have driven generic prices down, sometimes to just a few cents per vial. With thin profit margins, generic manufacturers cannot afford to maintain redundant production lines, invest in advanced manufacturing technologies, or source raw materials from multiple suppliers.
Single-Source Key Starting Materials (KSMs)
According to the U.S. Pharmacopeia, approximately 44% of the active ingredients used in shortage drugs are sourced from a single country—primarily India and China. When a regional regulatory change, natural disaster, or geopolitical disruption halts production at a single KSM facility, the entire downstream global supply chain stalls.
Regulatory and Manufacturing Complexity
Unlike simple small-molecule tablets, sterile injectables cannot be easily shifted to alternative manufacturing sites. Moving a biologic or sterile injection to a new plant requires a formal post-approval supplement, which involves conducting compatibility studies, demonstrating bioequivalence, and undergoing FDA facility inspections. This regulatory process typically takes 18 to 24 months, preventing rapid capacity adaptation.
Case Studies in Vulnerability
The vulnerability of this consolidated supply chain is demonstrated by two recent events:
- The Rocky Mount Tornado (July 2023): An EF3 tornado struck Pfizer's Rocky Mount, North Carolina manufacturing facility. The storm damaged storage warehouses holding finished products and raw materials. Because this single plant produced nearly 25% of all sterile injectables used in US hospitals, the incident immediately triggered national shortages of bupivacaine, lidocaine, and sodium chloride injections.
- Hurricane Helene and the Marion IV Plant (September 2024): Hurricane Helene caused historic flooding in western North Carolina, shutting down Baxter International’s Marion facility. The plant manufactured approximately 60% of the nation's IV solutions and peritoneal dialysis bags. The shutdown forced hospitals nationwide to implement strict IV fluid conservation protocols, highlighting the systemic risk of single-site concentration.
To explore how oncology practices specifically manage supply risk during shortages of essential cancer therapies, see our clinical review: cisplatin and carboplatin oncology injectable shortage.
FAQs
Why do sterile injectables account for most drug shortages?
Sterile injectables require highly complex, aseptic manufacturing environments to prevent bacterial contamination. Because sterile injectables must be free of pyrogens and particulates, any quality failure on the filling line requires shutting down the facility for remediation. When combined with low profit margins, these quality failures lead to frequent and persistent shortages.
How many manufacturers supply a typical generic sterile injectable, and why does that matter?
For many essential sterile injectables, only one or two manufacturers supply the entire US market. This lack of redundancy means that a quality recall or facility shutdown at a single site immediately triggers a national shortage, leaving hospitals with no alternative source of supply.
What is the difference between a molecule-level and a presentation-level shortage count?
A molecule-level shortage tracks the generic drug itself (e.g., cisplatin), whereas a presentation-level shortage tracks the specific strength, volume, and packaging (e.g., 50 mg/50 mL vial). The FDA database tracks shortages at the presentation level, which reflects the specific packaging configurations that hospital pharmacies buy.
What federal policies (PASTEUR-style subscriptions, manufacturing quality) are being proposed?
Proposed policies include the PASTEUR Act, which would establish a value-based subscription model paying manufacturers a flat annual fee to guarantee supply of critical antimicrobials. Additionally, the FDA and USP have proposed "Quality Maturity Ratings" (QMR) to reward manufacturers that invest in supply-chain redundancy and facility upgrades.
Sources
- U.S. Food and Drug Administration. "FDA Drug Shortages Database." Full presentation-level registry extract. Available at: FDA Drug Shortages
- U.S. Pharmacopeia (USP). "2026 Annual Drug Shortages Report." Published June 9, 2026. Available at: USP Publications
- HHS Assistant Secretary for Planning and Evaluation (ASPE). "National Drug Shortages: Efficacy, Duration, and Economic Drivers (2018-2023)." Published January 10, 2025. Available at: ASPE Data Briefs
- American Society of Health-System Pharmacists (ASHP). "ASHP-Utah Drug Information Service Shortage Statistics." Available at: ASHP Drug Shortages
- Brookings Institution. "Federal Policies to Address Persistent Generic Drug Shortages." Published 2024. Available at: Brookings Policy Research
